Circulating T cells of patients with active psoriasis respond to streptococcal M-Peptides sharing sequences with human epidermal keratins

Scandinavian Journal of Immunology

Volumn 45, Issue 6, 1997, Pages 688-697

  Sigmundsdottir, H ^a   Sigurgeirsson, B ^a   Troye Blomberg, M ^b   Good, M F ^c   Valdimarsson, H ^a   Jonsdottir, I ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; KERATIN; M PROTEIN;

ADULT; ARTICLE; ATOPIC DERMATITIS; BETA HEMOLYTIC STREPTOCOCCUS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE SUBPOPULATION;

EID: 0030966184     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-438.x     Document Type: Article

References (67)

1. Baker BS, Swain AF, Valdimarsson H, Fry L. T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol 1984;110:37-44.
2. Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T-lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984;110:555-64.
3. Bjerke JR, Krough HK, Matre R. Characterisation of mononuclear cell infiltrate in psoriatic lesions. J Invest Dermatol 1978;71:340.
4. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: a disease of abnormal proliferation induced by T lymphocytes. Immunol Today 1986;7:256-9.
5. Griffiths CEM, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J 1986;293:731-2.
6. Morel P, Revillard J-P, Nicolas J-F, Wijdenes J, Rizova H, Thivolet J. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmunity 1992;5:465-77.
7. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87.
8. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenesis basis. Nature Medicine 1996;1:442-7.
9. Whyte HJ, Baughman RD. Acute guttate psoriasis in streptococcal infections. Arch Dermatol 1964;89:350-6.
10. Norrlind R. Significance of infection in origin of psoriasis. Acta Rheumatol Scand 1955;1:135-44.
11. Telfer NR, Chalmers RJG, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992;128:39-42.
12. Manjula BN, Trus BL, Fishetti VA. Presence of the distinct regions in the coiled-coil structure of the streptococcal PepM5 protein: Relationship to mammalian coiled-coil proteins and implications to its biological properties. Proc Natl Acad Sci USA 1985;82: 1064-8.
13. Kehoe MA. Group A streptococcal antigens and vaccine potential. Vaccine 1991;9:797-806.
14. Robinson JH, Atherton MC, Goddacre JA, Pinkney M, Weightman H, Kehoe MA. Mapping T-cell epitopes in group A streptococcal type 5 M-protein. Infect Immun 1991;59:4324-31.
15. McFadden J, Valdimarsson H, Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. British Journal of Dermatology 1991;125:443-7.
16. Valdimarsson H, Baker BS, Jónsdóttir I, Powles AP, Fry L. Psoriasis - a T-cell mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995;16:145-9.
17. Aoki S, Yaoita H, Kitajima Y. An elevated level of autoantibodies against 48- to 50- kd keratins in the serum of patients with psoriasis. J Invest Dermatol 1989;92:179-83.
18. Wongwaisayawan H, Yoshiike T, Aikawa Y, Briggaman RA, Ogawa H. Antikeratin 14 monoclonal antibody staining in psoriasis and seborrhoeic keratosis: immunofluorescence and two colour FACS studies. Arch Dermatol Res 1991;283:405-10.
19. McGuire J, Osber M, Lightfoot L. Two keratins MW 50.000 and 56.000 are synthesized by psoriatic epidermis. Br J Dermatol 1984;111:27-37.
20. Leigh IM, Navsaria H, Purkis PE, Bowden PE, Riddle PN. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 1995;133:501-11.
21. Swerlick RA, Cunningham MW, Hall NK. Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic skin. J Invest Dermatol 1986;87:367-71.
22. Baker BS, Powles AV, Malkani AK, Lewis H, Valdimarsson H, Fry L. Altered cell-mediated immunity to group A haemolytic streptococcal antigens in chronic plaque psoriasis. Br J Immunol 1991;125:38-42.
23. Baker BS, Bokth SB, Garioch JJ et al. Decreased T cell reactivity to trypsinized group A, type 22 streptococci in psoriasis. Acta Derm Venerol 1994;74:276-8.
24. McFadden JP, Quinn DG, Camp RDR. In vitro lymphocyte response to streptococcal M protein in psoriasis. Biochem Soc Trans 1991;19:115.
25. Baker BS, Bokth S, Powles A et al. Group A streptococcal antigen-specific T-lymphocytes in guttate psoriatic lesions. Br J Dermatol 1993;128:493-9.
26. Carapetis JR, Currie BJ, Good MF. Towards understanding the pathogenesis of rheumatic lever. Scand J Rheumatol 1996;25:127-31.
27. Read SW, Zabrisky JB, Fischetti V, Utermohlen V, Falk R. Cellular reactivity studies to streptococcal antigens. Migration inhibition studies in patients with streptococcal infections and rheumatic lever. J Clin Invest 1974;54:439.
28. Kemeny E, Grieve T, Marcus R, Sareli P, Zabriesky JB. Identification of mononuclear cells and T-cell subsets in rheumatic valvulitis. Immunol Immunopathol 1989;52:225.
29. Pruksakorn S, Currie B, Brandt E et al. Identification of T-cell autoepitopes that cross-react with the carboxyterminal segment of the M protein of group A streptococci. Int Immunol 1994;6:1235-44.
30. Romagnani S. Lymphokine production by human T cells in disease stages. Annu Rev Immunol 1994;12:227-57.
31. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102: 145-9.
32. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesional-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993;101:701-5.
33. Barna M, Snidjewint FGM, van der Heijden FL, Bos JD, Kapsenberg ML. Characterization of lesional psoriatic skin T lymphocyte clones. Acta Derm Venereol 1991;186:9-11.
34. Baker BS, Powles AV, Valdimarsson H, Fry L. An altered response by psoriatic keratinocytes to gamma interferon. Scand J Immunol 1988;28:735-40.
35. Nickoloff BJ, Mitra RS, Elder RT, Ficher GJ, Voorhees JJ. Decreased growth inhibition by recombinant transforming growth factor-a in keratinocytes cultured from psoriatic lesions. Br J Dermatol 1989;121:161-74.
36. Scheynius A, Fransson J, Johansson C et al. Expression of interferon-gamma receptors in normal and psoriatic skin. J Invest Dermatol 1992;98:255-8.
37. Vollmer S, Mensen A, Trommler P, Schendel D, Prinz JC. T-lymphocytes derived from skin-lesions of patients with psoriatic vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994;24:2377-83.
38. Prinz JC, Gross B, Vollmer S et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994;24:593-8.
39. Frederikson T, Petterson U. Severe psoriasis-oral therapy with a new retinoid. Dermalogica 1978;157:238-44.
40. Olafsson JH, Sigurgeirsson B, Palsdottir R. The effect bathing in a thermal lagoon in Iceland has on psoriasis. J Eur Acad Dermatol Venerol 1994;3:460-4.
41. Pruksakorn S, Galbraith A, Houghton RA, Good MF. Conserved T and B cell epitopes on the M-protein of group A streptococci. J Immunol 1992;148:2729-35.
42. Houghten RA. General method for rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 1988;82:5131-5.
43. Rieger M, Franke WW. Identification of an orthologous mammalian cytokeratin gene. High degree in intron sequence conservation during evolution of human cytokeratin 10. J Mol Biol 1988;204:841-56.
44. Kuruc N, Leube RE, Moll I, Bader BL, Franke WW. Synthesis of cytokeratin 13, a component characteristic of internal stratified epithelia, is not induced in human epidermal tumors. Differentiation 1989;42:111-23.
45. Marchuk D, McCronon S, Fuchs E. Remarkable conservation of structure among intermediate filament genes. Cell 1984;39:491-8.
46. Troyanovsky SM, Leube RE, Franke WW. Characterization of the human gene encoding cytokeratin 17 and its expression pattern. Eur J Cell Biol 1992;59:127-37.
47. Rasmussen HH, van Damme J, Puype M, Gesser B, Celis JE, Vandekerchove J. Microsequence of 145 protein recorded in the two-dimensional gel protein database of normal human epidermal keratinocytes. Electrophoresis 1992;13:960-9.
48. Langbein L, Heid HW, Moll I, Franke WW. Molecular characterization of the body-site specific human epidermal cytokeratin 9: cDNA cloning amino acid sequences, and tissue specificity of gene expression. Differentiation 1993;55:57-72.
49. Leube RE, Bader BL, Nosch FX, Zimbelmann R, Achtstaetter T, Franke WW. Molecular expression of the stratification-related cytokeratins 4 and 15. J Cell Biol 1991;106:1249-61.
50. Rosenberg M, RayChaudhury A, Shows TB, Le Beau MM, Fuchs E. A group of type 1 keratin genes on human chromosome 17; characterization and expression. Mol Cell Biol 1988;8:722-36.
51. Kulesh DA, Oshima RG. Complete structure of the gene for human keratin 18. Mol Cell Biol 1988;8:1540-50.
52. Perlmann H, Perlmann P, Pape GR, Hallden G. Purification and assay of antibody dependent lymphocytic effector cells (K-cells) in human blood. Scand J Immunol 1976;5:57-63.
53. Jonsdottir I, Dillner-Centerlind ML, Perlmann H, Perlmann P. Antibody dependent cellular cytotoxicity and mitogen responsiveness of human peripheral blood lymphocytes differing in avidity for sheep erythrocytes. Scand J Immunol 1979;10:525-33.
54. Gabrielsson S, Paulis S, Rak S et al. Specific induction of interleukin-4-producing cells in response to in vitro allergen stimulation in atopic individuals. Clin Exp Allergy 1997 (in press).
55. Czerkinsky C, Anderson G, Ekre HP, Nilson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analyses of cytokine production. J Immunol Methods 1988;110:29-36.
56. Kabilan L, Anferson G, Lolli F, Ekre H, Troye-Blomberg M. Detection of intracellular expression and secretion of IFNγ at the single cell level after activation of human T-cells with tetanus toxoid in vitro. Eur J Immunol 1990;20:1085-9.
57. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
58. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 1995;181:1945-8.
59. Del Prete G, Maggi E, Romagnani S. Biology of disease. Human Th1 and Th2 cells: functional properties, mechanism of regulation, and role in disease. Lab Invest 1994;70:299-306.
60. Grewe M, Gyufko K, Schöpf E, Krutmann J. Lesional expression of interferon-γ in atopic eczema. Lancet 1995;343:25-6.
61. Baker BS, Griffiths CEM, Lambert S et al. The effects of cyclosporin A on lymphocytes and dendritic sub-populations in psoriasis. Br J Dermatol 1987;116:503-10.
62. Baker BS, Swain AF, Griffiths CEM, Leonard JN, Fry L, Valdimarsson H. The effects of topical treatment with steroids and dithranol on epidermal T-lymphocytes and dendritic cells in psoriasis. Scand J Immunol 1985;22:471-7.
63. Krueger JG, Wolfe JT, Nabeya RT et al. Successful ultraviolet B treatment of psoriasis in accompanied by reversal of keratinocyte pathology and by selective depletion of intradermal T-cells. J Exp Med 1995;182:2057-68.
64. Schmied M, Breitskopf H, Gold R et al. Apoptosis of T-lymphocytes in experimental autoimmune encephalomyelitis. Am J Pathol 1996;143:446-52.
65. Bauer J, Wekerle H, Lassmann H. Apoptosis in brain-specific autoimmune disease. Curr Op Immunol 1995;7:839-43.
66. Kabilan L, Troye-Blomberg M, Perlmann H et al. T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc Natl Acad Sci 1988;85:5659-63.
67. Leung DYM, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. J Exp Med 1995;181:747-53.